Effect of Botox Injection in Anterior Belly of Digastric on Skeletal Relapse Following Mandibular Advancement Surgery
Primary Purpose
Orthognathic Relapse
Status
Not yet recruiting
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Botox
Sponsored by

About this trial
This is an interventional prevention trial for Orthognathic Relapse focused on measuring mandibular advancement, orthognathic relapse
Eligibility Criteria
Inclusion Criteria:
- Patients need bilateral sagittal split osteotomy for correction of skeletal class II malocclusion (mandibular retrognathism).
- Age of the patient above 18 years.
- All patients are free from any systemic disease that may affect normal bone healing.
Exclusion Criteria:
- Patient with history of facial bone trauma, cleft lip or palate.
- Intra-bony lesions or infections that may interfere with surgery.
- Previous orthognathic surgeries.
- Patients with relative contraindications to (BTX) injection such as pregnancy, lactation, neuromuscular diseases (e.g., myasthenia gravis), motor neuron disease, allergy to any of the components of (BTX).
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Botox injection group
placebo group
Arm Description
Botox injection in anterior belly of digastric before mandibular advancement orthognathic surgery
no injection before surgery
Outcomes
Primary Outcome Measures
relapse
relapse in mandibular advancement
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05573581
Brief Title
Effect of Botox Injection in Anterior Belly of Digastric on Skeletal Relapse Following Mandibular Advancement Surgery
Official Title
Effect of Botox Injection in Anterior Belly of Digastric on Skeletal Relapse Following Mandibular Advancement Surgery (Randomized Controlled Trial)
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 2023 (Anticipated)
Primary Completion Date
January 2025 (Anticipated)
Study Completion Date
January 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to test whether Botox injection in anterior belly of digastric muscle in BSSO for mandibular advancement surgery could reduce the tendency of postoperative relapse.
Research question:
(P) In patient has skeletal class II mandibular retrognathism, (I) will Botox injection in anterior belly of digastric. (O) Affect the relapse of the mandible after mandibular advancement orthognathic surgery?
Participants will be undergo Botox injection in anterior belly of digastric and bilateral sagittal split surgery
Detailed Description
In the intervention group:
Botulinum toxin type A will be first injected into anterior belly of digastric muscles 2-3 days prior to any surgical intervention (for the BTX to be clinically effective). A total of 20 U of Botox will be injected bilaterally by using 25g needle, 1 cc insulin syringe through extra oral approach in 4 point.
Intra-operative procedures:
Access through a vestibular Sagittal split incision for mandible will be carried out. Dissection and reflection to reach the bone will be carried out.
The cutting guide of the mandible will be placed onto the exposed bony surface and manipulated to the best fit. Then, the guide will be fixed using four 2.0-mm screws to avoid any mobilization during drilling of the reference holes. Sixteen reference holes will be established using the cutting guide; eight on each side.
Then, a reciprocating saw will be used to perform the planned bilateral sagittal split osteotomy. After adequate mandibular mobilization and removal of bony interferences, the mandible will be repositioned using the patient-specific osteosynthesis material guided by the previously established reference holes and fixed using 2.0-mm screws.
In Bi-max surgery the maxillary cutting guide will be fixed in the same manner and Lefort I osteotomy will be carried out.
After adequate mobilization, the maxilla will be repositioned by the patient specific osteosynthesis material using the reference holes made by cutting guide and fixed using 2.0-mm screws.
All incisions were closed with 4-0 resorbable sutures.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Orthognathic Relapse
Keywords
mandibular advancement, orthognathic relapse
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
randomized controlled trial
Masking
Care ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Botox injection group
Arm Type
Experimental
Arm Description
Botox injection in anterior belly of digastric before mandibular advancement orthognathic surgery
Arm Title
placebo group
Arm Type
No Intervention
Arm Description
no injection before surgery
Intervention Type
Drug
Intervention Name(s)
Botox
Other Intervention Name(s)
botulinum toxin type A
Intervention Description
Botulinum toxin type A will be first injected into anterior belly of digastric muscles 2-3 days prior to any surgical intervention (for the BTX to be clinically effective)(Sadick and Matarasso 2004). A total of 20 U of Botox will be injected bilaterally by using 25g needle, 1 cc insulin syringe through extraoral approach in 4 point
Primary Outcome Measure Information:
Title
relapse
Description
relapse in mandibular advancement
Time Frame
6 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patients need bilateral sagittal split osteotomy for correction of skeletal class II malocclusion (mandibular retrognathism).
Age of the patient above 18 years.
All patients are free from any systemic disease that may affect normal bone healing.
Exclusion Criteria:
Patient with history of facial bone trauma, cleft lip or palate.
Intra-bony lesions or infections that may interfere with surgery.
Previous orthognathic surgeries.
Patients with relative contraindications to (BTX) injection such as pregnancy, lactation, neuromuscular diseases (e.g., myasthenia gravis), motor neuron disease, allergy to any of the components of (BTX).
12. IPD Sharing Statement
Learn more about this trial
Effect of Botox Injection in Anterior Belly of Digastric on Skeletal Relapse Following Mandibular Advancement Surgery
We'll reach out to this number within 24 hrs